Background: Phosphodiesterase-5 (PDE-5) inhibitors
restore nitric oxide (NO) signaling and may reduce
circulating inflammatory markers, and improve metabolic
parameters through a number of mechanisms. Daily
administration of the PDE-5 inhibitor, tadalafil (TAD) may
attenuate inflammation; improve fasting plasma glucose and
triglyceride levels and body weight. This study aims to
evaluate the efficacy of low dose PDE-5 inhibitor, tadalafil
(TAD) in controlling dysglycemia and body weight in obese
diabetic men.
Methods: Forty obese men with type 2 diabetes aged 30-50
years incorporated in this study, all with A1c of 7-8.5%,
attending obesity unit in AL-Kindy college of medicine.
Weight, height, BMI, FPG, A1c, cholesterol, TG, HDL and
LDL measured for all and advised for low calories diet and
increasing exercise and randomized into 2 groups , first
(control) without and the second (therapy) with addition of
tadalafil 2.5mg/day for 8 weeks, then remeasure all the
parameters after. Results blotted in tables and statistical
analysis done using SPSS program and t-test.
Results: There was significant reduction in weight, BMI,
FPG, cholesterol, TG and LDL, while no significant change in A1c , and although there was elevation in HDL but was insignificant in control group. In therapy group both weight, BMI, FPG, A1c, cholesterol, TG, and LDL show significant reduction, with mild insignificant elevation in HD. When compare the results of both groups significant results appear in percentage of change of FPG and A1c in therapy group.
Conclusion: Low calories diet and exercise are effective in
reducing obesity parameters in type 2 diabetes, in addition,
improve dysglycemia and dyslipidemia , adding tadalafil
2.5mg/day can add beneficial effect specifically for FPG and
A1c significantly. |